
BeOne Medicines Korea secures expanded indications for PD-1 inhibitor Tevimbra
BeOne Medicines Korea, the newly rebranded Korean subsidiary of global oncology company BeOne Medicines (formerly BeiGene), announced that its PD-1 inhibitor Tevimbra (ingredient: tislelizumab) has received expanded approvals from the Ministry of Food and …